跳至主要内容
临床试验/NCT03058185
NCT03058185招募中不适用

Observatoire Des Patients Atteints De Laminopathies Et Emerinopathies (Observatory for PAtients with Laminopathies and Emerinopathies)

Pitié-Salpêtrière Hospital28 个研究点 分布在 1 个国家目标入组 800 人开始时间: 2013年7月11日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
800
试验地点
28
主要终点
Comprehensive clinical evaluation of individuals with geneticaly proven mutations in LMNA or EMD genes according to the study protocol, in order to evaluate disease progression

研究概览

简要总结

Laminopathies and emerinopathies are complex group of rare disorders due to mutations in A-type lamins (LMNA) and Emerin (EMD) genes. Among them, disorders affecting skeletal and/or cardiac muscles are the most frequent clinical manifestations, with cardiac disease being a major cause of death. Remarkable progress has been made in the description of the clinical and genetic spectrum of these diseases since the 1990's. Until now, precise phenotype/genotype relations remain elusive. As for several other neuromuscular disorders, apart from symptomatic treatments, there is currently no specific treatment to prevent or slow down the progression of the disease. The OPALE registry is a multicentre web-based registry dedicated to laminopathy and emerinopathy French patients. OPALE has been approved by ethical and regulatory authorities. Its main inclusion criteria is the presence of a proven pathogenic LMNA and/or EMD gene mutation.

The OPALE objectives are to provide a tool allowing detailed capture of patient genetic, neurological, cardiological, endocrinological and respiratory assessments, in order to allow i) precise disease natural history, ii) evaluation of different disease complication frequency and iii) identification of prognosis factors.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Presence of a proven pathogenic LMNA and/or EMD gene mutation
  • Regular followup in France.
  • Signed informed consent

排除标准

  • Signed informed refusal

结局指标

主要结局

Comprehensive clinical evaluation of individuals with geneticaly proven mutations in LMNA or EMD genes according to the study protocol, in order to evaluate disease progression

时间窗: yearly up to 10 years

Comprehensive clinical evaluation of individuals with geneticaly proven mutations in LMNA or EMD genes according to the study protocol, in order to evaluate disease progression

次要结局

未报告次要终点

研究者

发起方
Pitié-Salpêtrière Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Bruno Eymard

Clinical Professor-Neuromuscular Unit

Pitié-Salpêtrière Hospital

研究点 (28)

Loading locations...

相似试验